How Pharmas Can Help Private Health Insurers Achieve A Larger Role In China – McKinsey
This article was originally published in PharmAsia News
Burgeoning private health insurance in China has room for growth, and pharmaceutical companies can lend a hand. Roche has led the way, and there is plenty for other multinational drug and device manufacturers to gain, according to a recent McKinsey report.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
In a drastic move, China sends top physicians from around the country to Wuhan, finally allows a WHO expert delegation to visit hospitals in the outbreak's epicenter and welcomes foreign experts.